SCHEDULE 13G/A

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

Constellation Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

210373106

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Introductory Note: This Statement on Schedule 13G/A is filed on behalf of the following entities in respect of the common stock of Constellation Pharmaceuticals, Inc.:

· Venrock Associates V, L.P. (“VA-V”), a limited partnership organized under the laws of the State of Delaware;

· Venrock Partners V, L.P. (“VP-V”), a limited partnership organized under the laws of the State of Delaware;

· Venrock Entrepreneurs Fund V, L.P. (“VEF-V”), a limited partnership organized under the laws of the State of Delaware;

· Venrock Management V, LLC (“VM-V”), a limited liability company organized under the laws of the State of Delaware;

· Venrock Partners Management V, LLC (“VPM-V”), a limited liability company organized under the laws of the State of Delaware;

· VEF Management V, LLC (“VEFM-V”), a limited liability company organized under the laws of the State of Delaware;

· Venrock Healthcare Capital Partners II, L.P. (“VHCP-II”), a limited partnership organized under the laws of the State of Delaware;

· VHCP Co-Investment Holdings II, LLC (“VHCP-II Co-Invest”), a limited liability company organized under the laws of the State of Delaware;

· VHCP Management II, LLC (“VHCPM-II”), a limited liability company organized under the laws of the State of Delaware;

· Venrock Healthcare Capital Partners III, L.P. (“VHCP-III”), a limited partnership organized under the laws of the State of Delaware;

· VHCP Co-Investment Holdings III, LLC (“VHCP-III Co-Invest”), a limited liability company organized under the laws of the State of Delaware;

· VHCP Management III, LLC (“VHCPM-III”), a limited liability company organized under the laws of the State of Delaware;

· Bong Koh, a United States citizen; and

· Nimish Shah, a United States citizen.

Item 1.

(a) Name of Issuer

Constellation Pharmaceuticals, Inc.

(b) Address of Issuer’s Principal Executive Offices

215 First Street, Suite 200

Cambridge, Massachusetts 02142

Item 2.

(a) Name of Person Filing

Venrock Associates V, L.P.

Venrock Partners V, L.P.

Venrock Entrepreneurs Fund V, L.P.

Venrock Management V, LLC

Venrock Partners Management V, LLC

VEF Management V, LLC

Venrock Healthcare Capital Partners II, L.P.

VHCP Co-Investment Holdings II, LLC

VHCP Management II, LLC

Venrock Healthcare Capital Partners III, L.P.

VHCP Co-Investment Holdings III, LLC

VHCP Management III, LLC

Bong Koh

Nimish Shah

(b) Address of Principal Business Office or, if none, Residence

(c) Citizenship

Each of VA-V, VP-V, VEF-V, VHCP-II and VHCP-III are limited partnerships organized in the State of Delaware. Each of VM-V, VPM-V, VEFM-V, VHCP-II Co-Invest, VHCPM-II, VHCP-III Co-Invest and VHCPM-III are limited liability companies organized in the State of Delaware. Both Koh and Shah are United States citizens.

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

210373106

Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership

(a) Amount Beneficially Owned as of December 31, 2019:

(b) Percent of Class as of December 31, 2019:

(c) Number of shares as to which the person has, as of December 31, 2019:

(i) Sole power to vote or to direct the vote

(ii) Shared power to vote or to direct the vote

(iii) Sole power to dispose or to direct the disposition of

(iv) Shared power to dispose or to direct the disposition of

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of a Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: February 14, 2020

EXHIBITS

A: Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G/A filed with the Securities and Exchange Commission on October 9, 2019)

B: Power of Attorney for Bong Koh (incorporated by reference to Exhibit B to the Schedule 13G/A filed with the Securities and Exchange Commission on October 9, 2019)

C: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit C to the Schedule 13G/A filed with the Securities and Exchange Commission on October 9, 2019)